JP2002501609A - 化学治療剤を含む活性薬剤の正確な効能アッセイ方法 - Google Patents
化学治療剤を含む活性薬剤の正確な効能アッセイ方法Info
- Publication number
- JP2002501609A JP2002501609A JP50606998A JP50606998A JP2002501609A JP 2002501609 A JP2002501609 A JP 2002501609A JP 50606998 A JP50606998 A JP 50606998A JP 50606998 A JP50606998 A JP 50606998A JP 2002501609 A JP2002501609 A JP 2002501609A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- agent
- patient
- cell
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.a)患者の組織、細胞腹水または浸出流体の試料を採取し、 b)前記試料を多細胞粒子に分離し、 c)前記凝集性多細胞粒子から組織カルチャー単層を成長させ、 d)前記単層からの細胞を複数の分離した部位に接種し、かつ e)前記複数の部位を少なくとも1種の活性薬剤で処理し、次いで該部位にお ける前記細胞の少なくとも一種の薬剤に対する化学的な敏感性を調査する工程を 含む、患者の細胞の化学的な敏感性を調査する方法。 2.前記工程a)が、 a)患者の癌組織のサンプルから採取された試料を調製する工程をさらに含む 請求項1記載の方法。 3.前記複数の分離した部位が、さらに複数のウェルを含むプレートからなる請 求項1記載の方法。 4.前記工程e)が、 e)前記複数の部位を、種々の濃度の前記複数の活性薬剤で試験し、次いで単 一の濃度での単一の活性薬剤に付いての最適な化学的敏感性を調査する工程を更 に含む請求項1記載の方法。 5.前記工程e)が、 e)前記複数の部位を、前記複数の活性薬剤の少なくとも1種において初期細 胞毒性効果および長期間阻害効果の両方の調査を可能とするのに十分な時間 に亘って、複数の活性薬剤を用いて処理する工程を更に含む請求項1記載の方法 。 6.前記工程e)でアッセイされた化学的敏感性が、抗癌敏感性である請求項1 記載の方法。 7.前記工程d)が、テラサキディスペンサーを用いて行われる請求項1記載の 方法。 8.前記工程d)の細胞が、カルチャープレートにおける複数のウェルに接種さ れるのに先立って、懸濁液中で調製される請求項1記載の方法。 9.前記活性薬剤が、化学治療薬剤である請求項1記載の方法。 10.前記活性薬剤が、創傷治癒薬剤である請求項1記載の方法。 11.前記活性薬剤が、放射線治療薬剤および/または放射線治療鋭敏化薬剤ま たは放射線治療向上薬剤である請求項1記載の方法。 12.前記活性薬剤が、免疫治療薬剤である請求項1記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/679,056 | 1996-07-12 | ||
US08/679,056 US5728541A (en) | 1996-07-12 | 1996-07-12 | Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays |
PCT/US1997/011595 WO1998002038A1 (en) | 1996-07-12 | 1997-07-10 | Precise efficacy assay methods for active agents including chemotherapeutic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002501609A true JP2002501609A (ja) | 2002-01-15 |
JP4108128B2 JP4108128B2 (ja) | 2008-06-25 |
Family
ID=24725407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50606998A Expired - Fee Related JP4108128B2 (ja) | 1996-07-12 | 1997-07-10 | 化学治療剤を含む活性薬剤の正確な効能アッセイ方法 |
Country Status (13)
Country | Link |
---|---|
US (13) | US5728541A (ja) |
EP (1) | EP0912085B1 (ja) |
JP (1) | JP4108128B2 (ja) |
CN (1) | CN1143618C (ja) |
AT (1) | ATE360989T1 (ja) |
AU (1) | AU712302B2 (ja) |
BR (1) | BR9710348A (ja) |
CA (1) | CA2259984C (ja) |
DE (1) | DE69737684T2 (ja) |
ES (1) | ES2283022T3 (ja) |
IL (1) | IL127964A (ja) |
NZ (1) | NZ333830A (ja) |
WO (1) | WO1998002038A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160003761A (ko) * | 2013-04-25 | 2016-01-11 | 큐젤 에쓰아 | 세포 기반 약물 스크리닝 분석 방법 및 이의 용도 |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040072722A1 (en) * | 2002-10-10 | 2004-04-15 | Kornblith Paul L. | Methods for assessing efficacy of chemotherapeutic agents |
US20040023375A1 (en) * | 2002-07-30 | 2004-02-05 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays |
US6416967B2 (en) * | 1996-07-12 | 2002-07-09 | Precision Therapeutics, Inc. | Method of using multicellular particulates to analyze malignant or hyperproliferative tissue |
US5728541A (en) * | 1996-07-12 | 1998-03-17 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays |
US6171780B1 (en) | 1997-06-02 | 2001-01-09 | Aurora Biosciences Corporation | Low fluorescence assay platforms and related methods for drug discovery |
US6517781B1 (en) * | 1997-06-02 | 2003-02-11 | Aurora Biosciences Corporation | Low fluorescence assay platforms and related methods for drug discovery |
US6861035B2 (en) | 1998-02-24 | 2005-03-01 | Aurora Discovery, Inc. | Multi-well platforms, caddies, lids and combinations thereof |
DE19912798C1 (de) * | 1999-03-10 | 2000-02-17 | Andreas Jordan | Verfahren zur Kultivierung von Krebszellen aus Humangewebe und Vorrichtung zur Aufbereitung von Gewebeproben |
US20040086888A1 (en) * | 2001-10-18 | 2004-05-06 | Kornblith Paul L | Method for tandem genomic/proteomic analysis of proliferating cells |
US7276351B2 (en) * | 2003-09-10 | 2007-10-02 | Seahorse Bioscience | Method and device for measuring multiple physiological properties of cells |
US20070087401A1 (en) * | 2003-10-17 | 2007-04-19 | Andy Neilson | Analysis of metabolic activity in cells using extracellular flux rate measurements |
US8658349B2 (en) | 2006-07-13 | 2014-02-25 | Seahorse Bioscience | Cell analysis apparatus and method |
WO2005114178A1 (de) * | 2004-05-21 | 2005-12-01 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Multizelluläre testsysteme |
WO2007028146A2 (en) * | 2005-09-01 | 2007-03-08 | Precision Therapeutics, Inc. | Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics |
WO2008118846A1 (en) * | 2007-03-23 | 2008-10-02 | Precision Therapeutics, Inc. | Methods for evaluating angiogenic potential in culture |
US20090081639A1 (en) * | 2007-05-31 | 2009-03-26 | Phil Hill | Assay for sensitivity to chemotherapeutic agents |
EP2207892A4 (en) * | 2007-10-15 | 2010-12-08 | Precision Therapeutics Inc | METHOD FOR SELECTION OF ACTIVE AGENTS FOR CANCER TREATMENT |
WO2009054996A2 (en) * | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
CN102016581B (zh) | 2008-02-25 | 2014-07-30 | 雀巢产品技术援助有限公司 | 用抗体阵列选择乳腺癌治疗药物 |
US20100311084A1 (en) * | 2008-05-14 | 2010-12-09 | Precision Therapeutics, Inc. | Methods for predicting a patient's response to egfr inhibitors |
WO2009140508A2 (en) * | 2008-05-14 | 2009-11-19 | Precision Therapeutics, Inc. | Methods for predicting a patient's response to egfr inhibitors |
EP3266453A1 (en) | 2008-07-03 | 2018-01-10 | Mayo Foundation for Medical Education and Research | Treating cancer |
US8202702B2 (en) * | 2008-10-14 | 2012-06-19 | Seahorse Bioscience | Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision |
US20110238322A1 (en) * | 2008-11-03 | 2011-09-29 | Precision Therapeutics, Inc. | Methods of simulating chemotherapy for a patient |
US20100152762A1 (en) * | 2008-12-16 | 2010-06-17 | Mark Joseph L | Tissue removal system with multi-directional foot actuator assembly for neurosurgical and spinal surgery applications |
US9655639B2 (en) * | 2008-12-16 | 2017-05-23 | Nico Corporation | Tissue removal device for use with imaging devices in neurosurgical and spinal surgery applications |
US9216031B2 (en) | 2008-12-16 | 2015-12-22 | Nico Corporation | Tissue removal device with adjustable fluid supply sleeve for neurosurgical and spinal surgery applications |
US10080578B2 (en) | 2008-12-16 | 2018-09-25 | Nico Corporation | Tissue removal device with adjustable delivery sleeve for neurosurgical and spinal surgery applications |
US8496599B2 (en) * | 2008-12-16 | 2013-07-30 | Nico Corporation | Tissue removal device for neurosurgical and spinal surgery applications |
US9504247B2 (en) | 2008-12-16 | 2016-11-29 | Nico Corporation | System for collecting and preserving tissue cores |
US8357175B2 (en) * | 2008-12-16 | 2013-01-22 | Nico Corporation | Positioning system for tissue removal device |
US9279751B2 (en) | 2008-12-16 | 2016-03-08 | Nico Corporation | System and method of taking and collecting tissue cores for treatment |
US8430825B2 (en) | 2008-12-16 | 2013-04-30 | Nico Corporation | Tissue removal device for neurosurgical and spinal surgery applications |
US8657841B2 (en) | 2008-12-16 | 2014-02-25 | Nico Corporation | Tissue removal device for neurosurgical and spinal surgery applications |
US9931105B2 (en) | 2008-12-16 | 2018-04-03 | Nico Corporation | System and method of taking and collecting tissue cores for treatment |
US9820480B2 (en) | 2008-12-16 | 2017-11-21 | Nico Corporation | System for collecting and preserving tissue cores |
US8702738B2 (en) * | 2008-12-16 | 2014-04-22 | Nico Corporation | Tissue removal device for neurosurgical and spinal surgery applications |
US10368890B2 (en) | 2008-12-16 | 2019-08-06 | Nico Corporation | Multi-functional surgical device for neurosurgical and spinal surgery applications |
US8460327B2 (en) * | 2008-12-16 | 2013-06-11 | Nico Corporation | Tissue removal device for neurosurgical and spinal surgery applications |
US20110014644A1 (en) | 2009-06-22 | 2011-01-20 | Precision Therapeutics, Inc. | Methods for predicting a cancer patient's response to antifolate chemotherapy |
JP5795311B2 (ja) | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
US20110097748A1 (en) * | 2009-10-28 | 2011-04-28 | Warsaw Orthopedic, Inc. | Use of cell lines to determine levels of efficacy of pharmaceutical formulations |
CN102947710B (zh) | 2010-01-28 | 2015-01-14 | 3D生物母体公司 | 悬滴装置、系统和/或方法 |
US9427477B2 (en) | 2011-05-09 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Cancer treatments |
EP2753175B1 (en) * | 2011-09-07 | 2019-02-06 | The Scripps Research Institute | Chiral compounds of varying conformational rigidity and methods of synthesis |
AU2013209737B2 (en) | 2012-01-17 | 2017-10-05 | Nico Corporation | System for collecting and preserving tissue cores |
CN104884960A (zh) * | 2012-07-05 | 2015-09-02 | 卡尔德拉健康有限责任公司 | 确定用于前列腺癌和乳腺癌的个体化治疗组合物的方法 |
EP3967306A1 (en) | 2012-10-01 | 2022-03-16 | Mayo Foundation for Medical Education and Research | Cancer treatments |
EP2920292B1 (en) | 2012-11-13 | 2017-01-11 | Agilent Technologies, Inc. | Apparatus and methods for three-dimensional tissue measurements based on controlled media flow |
CA2908117A1 (en) * | 2013-03-28 | 2014-10-02 | Centre Hospitalier Universitaire De Montpellier | Method for determining radiosensitivity |
DE102013010528B3 (de) * | 2013-06-25 | 2014-02-20 | FLACOD GmbH | Verfahren zur Erstellung einer Datenbank für die Vorabschätzung der Wirksamkeit von Wirkstoffen in der Tumortherapie |
JP6739351B2 (ja) | 2014-06-02 | 2020-08-12 | シーホース バイオサイエンス インコーポレイテッド | 生物試料分析用の単一列マイクロプレートシステム及び搬送体 |
KR20210125603A (ko) | 2014-06-16 | 2021-10-18 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 골수종의 치료 |
CA2951712A1 (en) * | 2014-06-20 | 2015-12-23 | Ross BEIGHLEY | Automated cell culture system and corresponding methods |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體-抗體組合物及其製造及使用方法 |
TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
AU2017217881B2 (en) | 2016-02-12 | 2022-11-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
EP3506942B1 (en) | 2016-09-01 | 2022-11-16 | Mayo Foundation for Medical Education and Research | Carrier-pd-l1 binding agent compositions for treating cancers |
AU2017321798B2 (en) | 2016-09-01 | 2023-06-15 | Mayo Foundation For Medical Education And Research | Methods and compositions for targeting T-cell cancers |
CN109890422A (zh) | 2016-09-06 | 2019-06-14 | 梅约医学教育与研究基金会 | 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法 |
US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
JP2019526587A (ja) | 2016-09-06 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチMayo Foundation For Medical Education And Research | Pd−l1を発現する癌を処置する方法 |
US20190168213A1 (en) * | 2017-11-10 | 2019-06-06 | Reliant Immune Diagnostics, Inc. | System and method for determining efficacy and dosage using parallel/serial dual microfluidic chip |
CN116622801A (zh) * | 2023-07-24 | 2023-08-22 | 安泰康生物技术(北京)有限公司 | 一种患者来源超微组织培养药物敏感性检测方法 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4423145A (en) * | 1981-05-07 | 1983-12-27 | Stampfer Martha R | Enhanced growth medium and method for culturing human mammary epithelial cells |
US4668618A (en) | 1981-09-14 | 1987-05-26 | Thornthwaite Jerry T | Nuclear isolation medium and procedure for separating cell nuclei |
US4937187A (en) * | 1983-02-04 | 1990-06-26 | Brown University Research Foundation | Methods for separating malignant cells from clinical specimens |
US4559299A (en) | 1983-02-04 | 1985-12-17 | Brown University Research Foundation Inc. | Cytotoxicity assays in cell culturing devices |
US4816395A (en) | 1985-12-19 | 1989-03-28 | Peralta Cancer Research Institute | Method for predicting chemosensitivity of anti-cancer drugs |
US4937182A (en) | 1985-12-19 | 1990-06-26 | Peralta Cancer Research Institute | Method for predicting chemosensitivity of anti-cancer drugs |
US5266480A (en) * | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
US4996145A (en) | 1987-10-27 | 1991-02-26 | Oncotech Incorporated | Method for detecting immune-mediated cytotoxicity |
US5258541A (en) * | 1988-02-16 | 1993-11-02 | Daicel Chemical Industries, Ltd. | Process for producing carbonic acid ester |
US5242806A (en) * | 1990-05-07 | 1993-09-07 | Baxter Diagnostics Inc. | Method for conducting the cytotoxicity assays on tumor cells |
US5874218A (en) | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
US5270172A (en) * | 1991-04-26 | 1993-12-14 | Dekk-Tek, Inc. | Method to predict tumor response to therapy |
US5407653A (en) | 1991-06-26 | 1995-04-18 | Brigham And Women's Hospital | Evaluation of the multidrug resistance phenotype |
US5837747A (en) | 1991-10-29 | 1998-11-17 | Vivorx, Inc. | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
WO1994000470A1 (en) | 1992-06-30 | 1994-01-06 | The Wistar Institute Of Anatomy And Biology | DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES |
US7166423B1 (en) * | 1992-10-21 | 2007-01-23 | Miltenyi Biotec Gmbh | Direct selection of cells by secretion product |
US5856112A (en) * | 1994-06-16 | 1999-01-05 | Urocor, Inc. | Method for selectively inducing biomarker expression in urologic tumor tissue for diagnosis and treatment thereof |
GB9419716D0 (en) | 1994-09-30 | 1994-11-16 | Gearey David | Electrochemical assessment of cell behaviour and metabolic activity |
US5607918A (en) | 1995-03-01 | 1997-03-04 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-B and DNA coding therefor |
US5888765A (en) | 1995-06-23 | 1999-03-30 | President And Fellows Of Harvard College | Endothelial-cell specific promoter |
US6274576B1 (en) | 1995-06-27 | 2001-08-14 | The Henry Jackson Foundation For The Advancement Of Military Medicine | Method of dynamic retardation of cell cycle kinetics to potentiate cell damage |
US6020473A (en) | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
US5942385A (en) | 1996-03-21 | 1999-08-24 | Sugen, Inc. | Method for molecular diagnosis of tumor angiogenesis and metastasis |
US20040072722A1 (en) | 2002-10-10 | 2004-04-15 | Kornblith Paul L. | Methods for assessing efficacy of chemotherapeutic agents |
US6416967B2 (en) * | 1996-07-12 | 2002-07-09 | Precision Therapeutics, Inc. | Method of using multicellular particulates to analyze malignant or hyperproliferative tissue |
US20020168679A1 (en) | 1998-06-11 | 2002-11-14 | Gregory J. Naus | Staining agents and protocols for characterizing malignant cells in culture |
US5728541A (en) | 1996-07-12 | 1998-03-17 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays |
US20040023375A1 (en) | 2002-07-30 | 2004-02-05 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays |
US6008007A (en) | 1997-01-31 | 1999-12-28 | Oncotech, Inc. | Radiation resistance assay for predicting treatment response and clinical outcome |
US5840507A (en) | 1997-03-19 | 1998-11-24 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis |
US5972639A (en) | 1997-07-24 | 1999-10-26 | Irori | Fluorescence-based assays for measuring cell proliferation |
US6111092A (en) | 1998-06-03 | 2000-08-29 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding DRT111 and uses thereof |
US6537759B1 (en) | 1998-07-20 | 2003-03-25 | Variagenics, Inc. | Folylpolyglutamate synthetase gene sequence variances having utility in determining the treatment of disease |
WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
CA2390305A1 (en) | 1999-11-03 | 2001-05-10 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis |
AU2002224435A1 (en) | 2000-10-18 | 2002-04-29 | Precision Therapeutics, Inc. | Method for tandem genomic/proteomic analyses of proliferating cells |
WO2002081734A1 (en) * | 2001-04-06 | 2002-10-17 | Department Of Veterans Affairs | Methods for modeling infectious disease and chemosensitivity in cultured cells and tissues |
US20040086888A1 (en) | 2001-10-18 | 2004-05-06 | Kornblith Paul L | Method for tandem genomic/proteomic analysis of proliferating cells |
JP2005508653A (ja) * | 2001-11-13 | 2005-04-07 | イェシバ・ユニバーシティ | 新規サイトヒン遺伝子およびこれの使用 |
US6900017B2 (en) * | 2002-01-10 | 2005-05-31 | The Board Of Trustees Of The University Of Illinois | Human hematopoietic growth regulatory gene and uses |
JP4175215B2 (ja) * | 2003-08-08 | 2008-11-05 | 日産自動車株式会社 | バイポーラ電池、組電池、複合組電池、および組電池または複合組電池を用いた車両 |
JP2008526889A (ja) * | 2005-01-10 | 2008-07-24 | リサーチ ディベロップメント ファウンデーション | 癌治療のための標的化キメラ分子 |
WO2007028146A2 (en) * | 2005-09-01 | 2007-03-08 | Precision Therapeutics, Inc. | Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics |
-
1996
- 1996-07-12 US US08/679,056 patent/US5728541A/en not_active Expired - Lifetime
-
1997
- 1997-07-10 JP JP50606998A patent/JP4108128B2/ja not_active Expired - Fee Related
- 1997-07-10 ES ES97933267T patent/ES2283022T3/es not_active Expired - Lifetime
- 1997-07-10 AT AT97933267T patent/ATE360989T1/de not_active IP Right Cessation
- 1997-07-10 CA CA002259984A patent/CA2259984C/en not_active Expired - Lifetime
- 1997-07-10 EP EP97933267A patent/EP0912085B1/en not_active Expired - Lifetime
- 1997-07-10 CN CNB971961433A patent/CN1143618C/zh not_active Expired - Fee Related
- 1997-07-10 NZ NZ333830A patent/NZ333830A/xx unknown
- 1997-07-10 AU AU36493/97A patent/AU712302B2/en not_active Ceased
- 1997-07-10 DE DE69737684T patent/DE69737684T2/de not_active Expired - Lifetime
- 1997-07-10 BR BR9710348-9A patent/BR9710348A/pt not_active Application Discontinuation
- 1997-07-10 IL IL12796497A patent/IL127964A/en not_active IP Right Cessation
- 1997-07-10 WO PCT/US1997/011595 patent/WO1998002038A1/en active IP Right Grant
-
1998
- 1998-03-16 US US09/039,957 patent/US6933129B1/en not_active Expired - Lifetime
- 1998-03-17 US US09/040,161 patent/US6900027B1/en not_active Expired - Lifetime
-
2002
- 2002-07-26 US US10/205,887 patent/US6887680B2/en not_active Expired - Lifetime
-
2005
- 2005-03-08 US US11/073,931 patent/US7112415B2/en not_active Expired - Lifetime
- 2005-03-17 US US11/081,827 patent/US7314731B2/en not_active Expired - Fee Related
-
2006
- 2006-08-15 US US11/504,098 patent/US7563593B2/en not_active Expired - Fee Related
-
2007
- 2007-11-26 US US11/944,884 patent/US7501260B2/en not_active Expired - Fee Related
-
2008
- 2008-09-10 US US12/208,076 patent/US7678552B2/en not_active Expired - Fee Related
- 2008-10-02 US US12/244,463 patent/US7771963B2/en not_active Expired - Fee Related
-
2010
- 2010-01-20 US US12/690,529 patent/US8183009B2/en not_active Expired - Fee Related
- 2010-07-01 US US12/828,665 patent/US8058025B2/en not_active Expired - Fee Related
-
2011
- 2011-10-06 US US13/267,581 patent/US20120088264A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160003761A (ko) * | 2013-04-25 | 2016-01-11 | 큐젤 에쓰아 | 세포 기반 약물 스크리닝 분석 방법 및 이의 용도 |
JP2016518129A (ja) * | 2013-04-25 | 2016-06-23 | キュー・ジェル・ソシエテ・アノニムQgel Sa | 細胞ベースの薬物スクリーニングアッセイの方法及びその使用 |
KR102255944B1 (ko) | 2013-04-25 | 2021-05-25 | 큐젤 에쓰아 | 세포 기반 약물 스크리닝 분석 방법 및 이의 용도 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002501609A (ja) | 化学治療剤を含む活性薬剤の正確な効能アッセイ方法 | |
US7972769B2 (en) | Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays | |
US6416967B2 (en) | Method of using multicellular particulates to analyze malignant or hyperproliferative tissue | |
US20020168679A1 (en) | Staining agents and protocols for characterizing malignant cells in culture | |
Walton et al. | Cell models in the study of mechanisms of toxicity | |
US6756194B2 (en) | Control samples for use as standards for evaluating apoptosis in a selected tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040712 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070227 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070416 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070604 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20071128 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080110 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080318 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080402 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110411 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120411 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120411 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130411 Year of fee payment: 5 |
|
LAPS | Cancellation because of no payment of annual fees |